Effect of Ocimum sanctum (Tulsi) aqueous leaf extract on prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) of human plasma
Keywords:
Ocimum sanctum, linolenic acid, anticoagulant, GCMS, coagulation assaysAbstract
Conventional anticoagulant therapy is the mainstay of medical treatment for deep vein thrombosis disorders. However, there are many complications associated with these agents such as bleeding. Hence, the search for novel anticoagulant derived from natural substances such as plants origin is in high demand nowadays. Ocimum sanctum (O. sanctum) also known as Ocimum tenuiform (OT), tulsi or holy basil from the family of Lamiaceae has been widely used for thousands of years in Ayurveda and Unani systems to cure or prevent a number of illnesses such as headache, malaria, ulcers, bronchitis, cough, flu, sore throat and asthma. The objective is to investigate the effect of O. sanctum (Tulsi) aqueous leaf extract on prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) in human plasma. Coagulation activity of O. sanctum was measured via PT, APTT and TT assay in citrated plasma collected from thirty-six healthy regular blood donors. The plasma was tested against different concentrations of O. sanctum aqueous extract as follows: 0.1mg/ml, 0.5 mg/ml and 1.0 mg/ml. Result shows the aqueous extract of O. sanctum prolonged the PT and APTT assays (p<0.05) but had no effect on TT assay (p>0.05). The gas chromatography-mass spectrometry (GC-MS) analysis had identified the linolenic acid at 1-10% of ethanol and aqueous concentration at different retention time which was responsible for the coagulation activities of O. sanctum in human plasma. This study suggests that O. sanctum does affect coagulation activity in human plasma and can be potentially used as naturally derived anticoagulant products in the future.References
Chen Y, Latha Y, Saravanan D, Sasidhara S, Sundram, K. Extraction, isolation and characterization of bioactive compounds from plant extracts. African Journal of Traditional, Complementary and Alternative Medicines (AJTCAM).2011; 8: pp.1-10.
Bauer K. Pros and cons of new oral anticoagulants. American Society of Hematology Education Program.2013;1: pp.464-470.
Gupta V, Kumar K, Kumar R, Singh A, Tripathi K, Triveni J. Ocimum sanctum Linn: A review on Phytopharmacology and therapeutic potential of tulsi. International Journal of Pharmaceutical Phytopharmacological Research.2013; 2: pp. 148-151.
Jung W, Je Y, Kim H, Kim S. A novel anticoagulant protein from Scapharca broughtonii. BMB Reports.2002; 35: pp. 199-205.
Shetty S, Somayaji N, Udupa S, Udupa L.Effect of Ocimum sanctum Linn on normal and dexamethasone suppressed wound healing. Indian Journal of Experimental Biology.2006; 1: pp.49-54.
Govindasamy S, Karthikeyan K, Ravichandran P. Chemopreventive effect of Ocimum sanctum on DMBA-induced hamster buccal pouch carcinogenesis. Oral Oncology.1999; 1: pp.112-119.
Gupta S, Mediratta P, Singh S, Sharma K, Shukla R. Antidiabetic antihypercholesterolaemic and antioxidant effect of Ocimum sanctum (Linn) seed oil. Indian Journal Experimental Biology.2006; 44: pp.300-304.
DeWitt D, Kelm M, Nair M, Stasburg G. Antioxidant and cyclooxygenase inhibitory phenolic compounds from Ocimum sanctum Linn. Phytomedicine.2000; 7: pp.7-13.
Rehan HMS, Singh S, Majumdar DK.Effect of Ocimum sanctum fixed oil on blood pressure, blood clotting time and pentobarbitone-induced sleeping time. Journal of Ethnopharmacology.2001; 78: pp.139-143.
Arulraj J, Lashmanan N, Shanmugaiah V. Studies on phytochemical analysis and antibacterial activity of Tulsi (Ocimum sanctum Linn) leaf extract against human and fish pathogens. International Journal of Advanced Life Sciences.2014; 7: pp.27-38.
Botinestean C, Hadaruga D, Hadaruga N, Jianu I. Fatty acids compositions by gas chromatography-mass spectrometry (GC-MS) and most important physical-chemicals parameters of tomato seed oil. Journal of Agroalimentary Processes and Technologies. 2012; 1: pp.89-94.
Choi PT, Douketis JD, Linkins LA. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med.2003; 139(11): pp.893–900.
Gangwal A. Extraction, Estimation and Thin Layer Chromatography of Tannins: A review. International Journal of Pharmaceutical and Chemical Sciences.2013; 2: pp.1585-1588.
Handa S, Khanuja S, Longo G, Rakesh D. Extraction technologies for medicinal and aromatic plants. Italy: International centre for science and high technology.2008;
Akremi N, Aouni M, Haloui E, Fenina N, Marzouk B, Marzouk Z. Antimicrobial and anticoagulation activities of Citrullus colocynthis Schrad. leaves from Tunisia (Medenine). African Journal of Pharmacy and Pharmacology.2012; 6: pp.1982-1988.
Félix-Silva J, Souza T, Camara RBBG, Cabral B, Silva-Júnior AA, Rebecchi IMM, et al. In vitro anticoagulant and antioxidant activities of Jatropha gossypiifolia L. (Euphorbiaceae) leaves aiming therapeutical applications. BMC Complementary and Alternative Medicine. 2014;14(1): pp. 405.
Thiruvenkatarajan V, Pruett A, Adhika S.D. Coagulation testing in the perioperative period. Indian Journal of Anaesthesia. 2014; 58(5): pp. 565–572.
Andy N, Pierce T. Conventional and near-patient test of coagulation. Journal of Anesthesia .2007;7: pp.45-50.
Kadian R, Parle M.Therapeutic potential and phytopharmacology of tulsi. International Journal of Pharmacy & Life Sciences.2012; 7:pp1-10.
Barja P, Guivernau M, Meza N, Roman O. Clinical and experimental study on the long-term effect of dietary gamma linolenic acid on plasma lipids, platelet aggregation, thromboxane formation, and prostacyclin production.
Prostaglandins, Leukotrienes and Essential Fatty Acids.1994 5: pp.311-316.
Gillingham L. The metabolic fate of alpha linolenic acid (ALA). The Journal of IHP-Continuing Education.2013; 1: pp.72-79.
Balasubramanian U, Devendran G. Qualitative phytochemical screening and GC-MS analysis of Ocimum sanctum L.leaves. Asian Journal of Plant science and Research.2011; 1: pp.44-48.
Gower A, Moura S, Rufatto L, Schwambach J.Mikania: chemical composition and phytotherapeutical activity. Brazilian Journal of Pharmacognosy.2012; 22: pp.1384-1403.
Downloads
Additional Files
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
